A Phase II Study of High Dose Cetuximab Plus Irinotecan in Colorectal Cancer Patients With KRS-Wild Type Tumors Who Progressed After Failure of Prior Standard Dose of Cetuximab Plus Irinotecan.
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2015
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 22 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Aug 2012 Planned end date changed from 1 Nov 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 12 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.